^
    over1year
    Novel GPC3xCD3 (NILK-2501) and GPC3xCD28 (NILK-3801) κλ Bispecific Antibodies for Next Generation Immunotherapy of GPC3-Expressing Solid Cancers (APASL 2023)
    The superagonistic monoclonal anti-human CD28 antibody (IgG4κ) TGN1412 was used as comparator. Activity is maintained while it allows well tailorable dose response with reduced cytokine release. Compounds are currently in extensive pre-clinical assessment 999
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    NILK-2501 • NILK-3801 • theralizumab (TAB08)